Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains

被引:61
作者
Laassri, M
Lottenbach, K
Belshe, R
Wolff, M
Rennels, M
Plotkin, S
Chumakov, K
机构
[1] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA
[2] EMMES Corp, Rockville, MD USA
[3] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[4] St Louis Univ, St Louis, MO 63103 USA
[5] Univ Penn, Philadelphia, PA 19104 USA
[6] Sanofi Pasteur, Doylestown, PA USA
关键词
D O I
10.1086/498172
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Inactivated poliovirus vaccine (IPV) is believed to induce significantly lower mucosal immunity than oral poliovirus vaccine (OPV). Most of the data supporting this were generated before enhanced IPV (eIPV) was introduced. Excretion of poliovirus by OPV recipients can be used to assess intestinal immunity. We studied polymerase chain reaction amplification of viral complementary DNA from the stool of children vaccinated with either OPV alone or eIPV. Of first-time OPV recipients, 92% excreted virus after 1 week, and 81% excreted virus after 3 weeks. Prior vaccination with OPV reduced the number to 22% and shortened the duration of virus excretion (to 5% after 3 weeks). Two doses of IPV reduced the number of poliovirus-positive 1-week samples (to 76%), the duration of shedding (to 37% at 3 weeks), and the quantity of excreted virus. This suggests that IPV-vaccinated communities are partially protected from the spread of poliovirus. Further enhancement of IPV potency may lead to even higher levels of mucosal immunity.
引用
收藏
页码:2092 / 2098
页数:7
相关论文
共 29 条
  • [1] *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P874
  • [2] *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P41
  • [3] Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P253
  • [4] Microarray analysis of evolution of RNA viruses: Evidence of circulation of virulent highly divergent vaccine-derived polioviruses
    Cherkasova, E
    Laassri, M
    Chizhikov, V
    Korotkova, E
    Dragunsky, E
    Agol, VI
    Chumakov, K
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (16) : 9398 - 9403
  • [5] Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine
    Cherkasova, EA
    Yakovenko, ML
    Rezapkin, GV
    Korotkova, EA
    Ivanova, OE
    Eremeeva, TP
    Krasnoproshina, LI
    Romanenkova, NI
    Rozaeva, NR
    Sirota, L
    Agol, VI
    Chumakov, KM
    [J]. JOURNAL OF VIROLOGY, 2005, 79 (02) : 1062 - 1070
  • [6] CONSISTENT SELECTION OF MUTATIONS IN THE 5'-UNTRANSLATED REGION OF ORAL POLIOVIRUS VACCINE UPON PASSAGING IN-VITRO
    CHUMAKOV, KM
    DRAGUNSKY, EM
    NORWOOD, LP
    DOUTHITT, MP
    RAN, YX
    TAFFS, RE
    RIDGE, J
    LEVENBOOK, IS
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1994, 42 (01) : 79 - 85
  • [8] Doi Y, 2001, Dev Biol (Basel), V105, P163
  • [9] Polio eradication: the OPV paradox
    Dowdle, WR
    De Gourville, E
    Kew, OM
    Pallansch, MA
    Wood, DJ
    [J]. REVIEWS IN MEDICAL VIROLOGY, 2003, 13 (05) : 277 - 291
  • [10] Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: A new surrogate method for predicting vaccine efficacy
    Dragunsky, EM
    Ivanov, AP
    Wells, VR
    Ivshina, AV
    Rezapkin, GV
    Abe, S
    Potapova, SG
    Enterline, JC
    Hashizume, S
    Chumakov, KM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (08) : 1404 - 1412